


An oral GLP-1 RA added to titrated basal insulin

ACHIEVE-5, a phase 3 trial published in JAMA, June 2026.
546 adults with type 2 diabetes, inadequately controlled on insulin glargine, given once-daily oral orforglipron or placebo over 40 weeks.

Mean HbA1c change at 40 weeks

Orforglipron once daily, change from baseline (%). Baseline mean 8.5%.



Every dose was **superior to placebo** (P<0.001).

BODY WEIGHT

-2.6% to -5.4%
across doses, vs +0.2% with placebo

HYPOGLYCAEMIA

No increase
in clinically significant events vs placebo

Giorgino F, et al. Orforglipron added to titrated insulin glargine in type 2 diabetes (ACHIEVE-5).
JAMA. Published online 7 June 2026. doi:10.1001/jama.2026.9512

Intended for UK healthcare professionals only.